Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients.

Scientific reports - 28 Oct 2020

Monti Paola, Lionetti Marta, De Luca Giuseppa, Menichini Paola, Recchia Anna Grazia, Matis Serena, Colombo Monica, Fabris Sonia, Speciale Andrea, Barbieri Marzia, Gentile Massimo, Zupo Simonetta, Dono Mariella, Ibatici Adalberto, Neri Antonino, Ferrarini Manlio, Fais Franco, Fronza Gilberto, Cutrona Giovanna, Morabito Fortunato

Abstract excerpt

Chronic lymphocytic leukaemia (CLL) is characterised by a heterogeneous clinical course. Such heterogeneity is associated with a number of markers, including TP53 gene inactivation. While TP53 gene alterations determine resistance to chemotherapy, it is not clear whether they can influence early disease progression. To clarify this issue, TP53 mutations and deletions of the corresponding locus [del(17p)] were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genes, p53
Share to Leukemia, Lymphocytic, Chronic, B-Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 33116240
DOI: 10.1038/s41598-020-75364-3
PMCID: PMC7595214

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients.PMID 33116240Read ↗

The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype.Semantic proximity Read ↗

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.Semantic proximity Read ↗

TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Association of gene mutations with time‐to‐first treatment in 384 treatment‐naive chronic lymphocytic leukaemia patientsSemantic proximity Read ↗

TP53 mutation and survival in chronic lymphocytic leukemia.Semantic proximity Read ↗

Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?Semantic proximity Read ↗

TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes.Semantic proximity Read ↗

Prognostication in chronic lymphocytic leukemia.Semantic proximity Read ↗

Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL.Semantic proximity Read ↗

The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.Semantic proximity Read ↗

A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in<i><scp>TP</scp>53</i>Semantic proximity Read ↗

TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.